Aims and objectives of this session
The aim of this session is to provide an update on novel approach to improve detection and outcomes of prostate cancer.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

344
Repeat prostate-specific antigen tests before prostate biopsy: A decreasing in PSA values is associated with a reduced risk of cancer and particularly high grade cancer
By: De Nunzio C., Lombardo R., Presicce F., Deroma M., Tema G., Cancrini F., Tubaro A.
Institutes: Sant’ Andrea Hospital - Sapienza University, Dept. of Urology, Rome, Italy

345
Atorvastatin before prostatectomy and prostate cancer - a randomized, double-blind, placebo controlled clinical trial
By: Murtola T.¹, Riikonen J.¹, Syvälä H.², Tolonen T.³, Koskimäki J.¹, Pakarainen T.¹, Kaipia A.⁴, Isotalo T.⁵, Kujala P.³, Tammela T.¹
Institutes: Tampere University Hospital, Dept. of Urology, Tampere, Finland, ²University of Tampere, School of Medicine, Tampere, Finland, ³Fimlab Laboratories, Dept. of Pathology, Tampere, Finland, ⁴Satakunta Central Hospital, Dept. of Urology, Pori, Finland, ⁵Päijät-Häme Central Hospital, Dept. of Urology, Lahti, Finland

346
The effect of metformin use and the incidence of prostate cancer in type 2 diabetes mellitus patients: A nationwide population-based study
By: Yun S.J.¹, Kim S.Y.², Park J-H.³, Cha I-C.⁴, Jeong P.⁵, Kang H.W.⁵, Ha Y-S.⁵, Kim W.T.⁵, Kim Y-J.², Lee S.C.³, Kim W-J.⁵
Institutes: ¹Chungbuk National University, Dept. of Urology, Cheongju, South Korea, ²Chungbuk National University Hospital, Office of Public Health, Cheongju, South Korea, ³College of Medicine, Chungbuk National University, Dept. of Preventive Medicine, Cheongju, South Korea, ⁴National Police Hospital, Dept. of Urology, Seoul, South Korea, ⁵Chungbuk National University College of Medicine, Dept. of Urology, Cheongju, South Korea, ⁶Kyungpook National University Medical Center, Dept. of Urology, Daegu, South Korea

347
An automated-microcapillary electrophoresis-based immunoassay system may improve diagnostic accuracy of prostate cancer and be a good indicator of biopsy Gleason score
By: Ishikawa T.¹, Yoneyama T.¹, Tobisawa Y.¹, Hatakeyama S.¹, Kurosawa T.², Nakamura K.², Koie T.¹, Hashimoto Y.¹, Ohyama C.¹
Institutes: ¹Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, ²Wako Pure Chemical Industries, Ltd., Diagnostics Research Laboratories, Amagasaki, Japan

348
Association between single nucleotide polymorphisms, gene expression and prostate cancer risk at the moment of diagnosis
By: Puche Sanz I.¹, Robles-Fernández I.², Pascual-Geler M.¹, Martinez-Gonzalez L.², Lorente J.A.², Cózar-Olmo J.M.¹, Álvarez-Cubero M.J.²
Institutes: ¹Complejo Hospitalario Universitario Granada, Dept. of Urology, Granada, Spain, ²Pfizer-
Clinical usefulness of eight novel monoclonal antibodies against prostate-specific antigen (PSA) to differentiate prostate cancer and benign prostate hyperplasia. Measurement of different PSA molecular forms with specific immunoassays
By: Navarro S.1, Royo M.2, Martos L.2, Vera Donoso C.D.1, Martinez-Sarmiento M.1, Alapont J.M.1, Ramon L.A.2, Oto J.3, España F.2, Medina-Badenes P.2
Institutes: La Fe, University and Polytechnic Hospital, Dept. of Urology, Valencia, Spain, 2Instituto De Investigación Sanitaria La Fe, Grupo De Hemostasia, Trombosis, Arteriosclerosis Y Biología Vascular, Valencia, Spain

Defining a cohort of men who may not require repeat prostate biopsy based on PCA3 and MRI: The double negative effect
By: Perlis N.1, Al-Kasab T.1, Ahmad A.1, Goldberg E.1, Fadak K.1, Sayyid R.1, Finelli A.1, Kulkarni G.1, Hamilton R.1, Zlotta A.2, Fleschner N.1
Institutes: University of Toronto, University Health Network, Dept. of Surgical Oncology, Division of Urology, Toronto, Canada, 2University of Toronto, University Health Network and Sinai Health System, Dept. of Surgical Oncology, Division of Urology, Toronto, Canada

Circulating tumor cells as a marker of bone metastases in patients with high-risk prostate cancer
By: Ciezlikowski W.A.1, Ida A.1, Hrab M.1, Budna J.2, Il wierczewska M.2, Jankowiak A.2, Zabel M.2, Antczak A.1
Institutes: Poznań University of Medical Sciences, Dept. of Urology, Poznań, Poland, 2Poznań University of Medical Sciences, Dept. of Histology and Embryology, Poznań, Poland

Clinical validation of a 17-gene genomic prostate score (GPS) assay as a predictor of distant metastases in men with prostate cancer (PCa) treated with radical prostatectomy (RP) in a community setting
By: Van Den Eeden S.1, Zhang N.4, Shan J.1, Quesenberry C.1, Han J.2, Tsiantis A.3, Lu R.4, Lawrence J.5, Febbo P.5, Presti J.6
Institutes: Kaiser Permanente Northern California, Dept. of Research, Oakland, United States of America, 2Kaiser Oakland Medical Center, Dept. of Pathology, Oakland, United States of America, 3Genomic Health, Dept. of Pathology, Redwood City, United States of America, 4Genomic Health, Dept. of Biostatistics, Redwood City, United States of America, 5Genomic Health Medical Department, Redwood City, United States of America, 6Kaiser Oakland Medical Center, Dept. of Urology, Oakland, United States of America

Serum miRNA-supported transrectal MRI-ultrasound fusion-guided biopsy of the prostate enhances tumor prediction and classification
By: Keck B., Wach S., Pöllmann J., Jansen T., Kahlmeyer A., Taubert H., Wullich B.
Institutes: University Hospital Erlangen, Dept. of Urology, Erlangen, Germany

The influence of physical activity on prostate cancer diagnosis: A multicenter biopsy cohort analysis
By: De Nunzio C.1, Cindolo L.2, Sountoulidis P.3, Toutziaris C.4, Gacci M.5, Presicce F.1, Cancrini F.1, Schips L.2, Semin S.6, Tubaro A.1
Institutes: Sant’Andrea Hospital - Sapienza University, Dept. of Urology, Rome, Italy, 2Padre Pio Da Pietrelcina Hospital, Dept. of Urology, Vasto, Italy, 3General Hospital of Veria, Dept. of Urology, Veria, Greece, 4Aristotle University of Thessaloniki, Dept. of Urology, Thessaloniki, Greece, 5Careggi Hospital, Dept. of Urology, Florence, Italy

Mutation of duffy antigen receptor for chemokines (DARC) as an indicator of prostate cancer severity in Afro-Caribbean men
By: Galustian C.1, Rani A.1, Cahill F.2, Santaolalla A.2, Gillett C.3, Lombardelli C.3, Rosekilly J.3, Sakellariou C.1, George G.2, Papaevangelou E.1, Smith R.4, Smolarek D.4, Van Hemelrijk M.2, Dasgupta P.4
Institutes: Kings College London, Innate Immunity, MRC Centre for Transplantation, London, EAU London 2017
Germline mutations in the Kallikrein 6 region and predisposition for aggressive prostate cancer

By: Briollais L.\(^2\), Ozcelik H.\(^2\), Xu J.\(^2\), Kwiatkowski M.\(^3\), Lalonde E.\(^4\), Sendorek D.\(^4\), Fleshner N.\(^4\), Recker F.\(^3\), Kuk C.\(^6\), Olkhov-Mitsel E.\(^3\), Savas S.\(^7\), Hanna S.\(^8\), Juvet T.\(^5\), Hunter G.\(^4\), Friedlander M.\(^2\), Li H.\(^2\), Chadwick K.\(^5\), Prassas I.\(^9\), Soosaipillai A.\(^3\), Randazzo M.\(^3\), Trachtenberg J.\(^5\), Toi A.\(^5\), Shiah Y-J.\(^4\), Fraser M.\(^10\), Van Der Kwast T.\(^11\), Bristow R.\(^10\), Bapat B.\(^2\), Diamandis E.\(^9\), Boutros P.\(^4\), Zlotta A.\(^1\)

Institutes: Mount Sinai Hospital, Dept. of Surgery (urology), Toronto, Canada, \(^2\)Mount Sinai Hospital, Lunenfeld-Tanenbaum Research Institute, Toronto, Canada, \(^3\)Cantonal Hospital Aarau, Dept. of Urology, Aarau, Switzerland, \(^4\)Ontario Institute For Cancer Research, Informatics & Biocomputing Program, Toronto, Canada, \(^5\)Princess Margaret Hospital, University Health Network, Dept. of Surgical Oncology, Urology, Toronto, Canada, \(^6\)Mount Sinai Hospital, Dept. of Surgery and Urology, Toronto, Canada, \(^7\)Memorial University, Craig L. Dobbin Genetics Research Centre, Discipline of Genetics, Faculty of Medicine, St. John's, Canada, \(^8\)Mount Sinai Hospital, Dept. of Surgery, Urology, Toronto, Canada, \(^9\)Mount Sinai Hospital, Dept. of Pathology and Laboratory Medicine, Toronto, Canada, \(^10\)Princess Margaret Hospital, University Health Network, Ontario Cancer Institute, Toronto, Canada, \(^11\)Toronto General Hospital, University Health Network, Dept. of Pathology, Toronto, Canada

Summary

A. Rannikko, Helsinki (FI)